AZD0486 is a fully human BiTE also targeting CD19, and CD3 is currently under evaluation in the Soundtrack-E phase I/II trial, either as a monotherapy or in combination with acalabrutinib in patients with R/R CLL/SLL (NCT06564038). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.